Clinical trial
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As…
NCT00174356 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00174356 |
|---|---|
| Title | PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients |
| Official title | A Phase 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel And Carboplatin As First-Line Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small Cell Lung |
| Intervention type | Drug |
| Interventions | CI 1033, PACLITAXEL, CARBOPLATIN |
| Enrollment | 39 |
| Start date | Dec 1, 2002 |
| Completion | Oct 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 8, 2006 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: